Tsai Hwei-Fang, Lai Jiann-Jyh, Chou Ai-Hsiang, Wang Ting-Fang, Wu Chien-Sheng, Hsu Ping-Ning
College of Medicine, National Taiwan University, and Taipei Ho-Ping Municipal Hospital, Taipei, Taiwan, Republic of China.
Arthritis Rheum. 2004 Feb;50(2):629-39. doi: 10.1002/art.20038.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has recently been shown to induce costimulation of mouse T cells in conjunction with signals from the T cell receptor. This study was undertaken to investigate TRAIL-induced costimulation of human T cells in order to determine the role of TRAIL-induced T cell activation in human systemic lupus erythematosus (SLE).
An in vitro T cell stimulation system with immobilized anti-CD3 and recombinant TRAIL receptor DR4-Fc proteins was used to activate human T cells purified from healthy individuals and from patients with SLE. The T cells were stimulated in vitro to assay their proliferation response by (3)H-thymidine incorporation, and their cytokine production by enzyme-linked immunosorbent assay. Activation of p38 MAPK after TRAIL stimulation was detected with specific anti-phospho-p38 MAPK monoclonal antibodies in Western blots.
Enhanced T cell proliferation and increased interleukin-2 and interferon-gamma (IFNgamma) production were demonstrated in human T cells after stimulation with immobilized DR4-Fc and anti-CD3 in vitro. TRAIL engagement selectively activated human CD4, rather than CD8, T cells and augmented IFNgamma production. Activation of p38 MAPK was detected after TRAIL-induced T cell activation. T cells isolated from patients with SLE demonstrated a stronger response to TRAIL-induced costimulation, in terms of proliferation and increased up-regulation of CD25 after activation, when compared with T cells from healthy subjects.
TRAIL engagement induces costimulation of human CD4 T cells via a p38 MAPK-dependent pathway. The results suggest that enhanced reactivity of T cells to autoantigens as a result of TRAIL-induced costimulation may play a role in the development of human autoimmune diseases.
肿瘤坏死因子相关凋亡诱导配体(TRAIL)最近被证明可与T细胞受体信号协同诱导小鼠T细胞共刺激。本研究旨在探讨TRAIL诱导的人T细胞共刺激,以确定TRAIL诱导的T细胞活化在人类系统性红斑狼疮(SLE)中的作用。
使用固定化抗CD3和重组TRAIL受体DR4-Fc蛋白的体外T细胞刺激系统来激活从健康个体和SLE患者中纯化的人T细胞。通过³H-胸腺嘧啶核苷掺入法体外刺激T细胞以检测其增殖反应,并通过酶联免疫吸附测定法检测其细胞因子产生。在蛋白质印迹中用特异性抗磷酸化p38 MAPK单克隆抗体检测TRAIL刺激后p38 MAPK的活化。
体外使用固定化DR4-Fc和抗CD3刺激后人T细胞表现出增强的T细胞增殖以及白细胞介素-2和干扰素-γ(IFNγ)产生增加。TRAIL结合选择性激活人CD4而非CD8 T细胞并增强IFNγ产生。在TRAIL诱导的T细胞活化后检测到p38 MAPK的活化。与健康受试者的T细胞相比,从SLE患者分离的T细胞在增殖和活化后CD25上调增加方面对TRAIL诱导的共刺激表现出更强的反应。
TRAIL结合通过p38 MAPK依赖性途径诱导人CD4 T细胞共刺激。结果表明,由于TRAIL诱导的共刺激导致T细胞对自身抗原的反应性增强可能在人类自身免疫性疾病的发展中起作用。